Nurix Therapeutics (NRIX) CFO sells 4,761 shares under 10b5-1 plan

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. reported that Chief Financial Officer Hans van Houte sold a total of 4,761 shares of common stock on August 4, 2026, in two open-market or private transactions at weighted average prices of $23.8911 and $24.6474 per share pursuant to a previously adopted Rule 10b5-1 trading plan, with sale prices ranging between $23.42 and $24.83.

Insider Trade Summary 10b5-1

Net Seller: 4,761 shares

Net Sell 2 txns

Insider van Houte Hans

Role Chief Financial Officer

Sold 4,761 shs ($116K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,794	$23.8911	$43K
Sale	Common Stock F1, F3	2,967	$24.6474	$73K

Holdings After Transaction: Common Stock — 40,166 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Total shares sold: 4,761 shares First tranche shares: 1,794 shares Second tranche shares: 2,967 shares +3 more

6 metrics

Total shares sold 4,761 shares Aggregate Nurix Therapeutics common shares sold by CFO Hans van Houte on August 4, 2026

First tranche shares 1,794 shares First reported sale of common stock by the CFO on August 4, 2026

Second tranche shares 2,967 shares Second reported sale of common stock by the CFO on August 4, 2026

Weighted average price (first sale) $23.8911 per share Weighted average sale price for 1,794 shares; price range $23.42–$24.39

Weighted average price (second sale) $24.6474 per share Weighted average sale price for 2,967 shares; price range $24.42–$24.83

Transaction date August 4, 2026 Date on which both non-derivative common stock sales were executed

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which"

open market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 09:41 PM Accepted by SEC EDGAR 08/04/2026 - 09:41 PM Learn about SEC filing dates

FAQ

What insider transaction did NRIX disclose for its Chief Financial Officer?

Nurix Therapeutics disclosed that CFO Hans van Houte sold 4,761 shares of NRIX common stock on August 4, 2026, in two transactions at weighted average prices of $23.8911 and $24.6474 per share under a Rule 10b5-1 trading plan.

How many NRIX shares did Hans van Houte sell in each transaction and at what prices?

Hans van Houte sold 1,794 shares at a weighted average price of $23.8911 (range $23.42–$24.39) and 2,967 shares at a weighted average price of $24.6474 (range $24.42–$24.83) of Nurix Therapeutics common stock.

Were the NRIX CFO stock sales made under a Rule 10b5-1 trading plan?

Yes. The report states the transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan, and the related affirmation box is checked, indicating these sales followed a pre-arranged, systematic trading program rather than discretionary timing.

What type of securities and transaction code are reported for NRIX in this insider trade?

The transactions involve Common Stock of Nurix Therapeutics, Inc. and are coded “S”, indicating a sale in open market or private transaction. Both entries are classified as non-derivative securities and are reported as directly owned by the CFO.

On what date did the NRIX Chief Financial Officer complete the reported stock sales?

Both sales by NRIX Chief Financial Officer Hans van Houte occurred on August 4, 2026. On that date he executed two separate common stock transactions totaling 4,761 shares at weighted average prices of $23.8911 and $24.6474 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Houte Hans

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2026		S(1)		1,794	D	$23.8911(2)	43,133	D
Common Stock	08/04/2026		S(1)		2,967	D	$24.6474(3)	40,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)